Search
forLearn
5 / 801 resultsResearch
5 / 93 results
research Irisin promotes hair growth and hair cycle transition by activating the GSK ‐3β/β‐catenin pathway
Irisin can promote hair growth by activating a specific signaling pathway.
research The Associations Between Serum Concentrations of Irisin and Glucose-dependent Insulinotropic Polypeptide with Body Mass Index Among Women with and Without Polycystic Ovary Syndrome
Irisin and GIP levels are not linked to BMI in women, regardless of PCOS status.
research A Comparative Analysis of Serum Irisin Levels and Body Composition Indices in Women With and Without Polycystic Ovary Syndrome (PCOS)
Women with PCOS have higher irisin levels, which may affect their metabolism and hormones.
research Serum betatrophin and irisin levels in patients with polycystic ovary syndrome with and without insulin resistance
Irisin and betatrophin levels change differently in PCOS, which may help assess metabolic risks.
research Circulating and/or cutaneous irisin resistance: A novel link among androgenetic alopecia, comorbid metabolic syndrome and cardiovascular risks
Androgenetic alopecia is linked to higher cardiovascular and metabolic risks, possibly due to irisin resistance.
Community Join
5 / 1000+ resultscommunity Rate my dutasteride stock on 10
Using Dutasteride as a hair loss treatment and its potential benefits, including availability in certain countries without a prescription and lower side effects than Minoxidil or RU58841.
community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
community Eirion ET-02( RS 5441) managed to defeat rodents, finally
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Shiseido RCH-01
Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.